Bristol-Myers Squibb Company Earnings Call Transcripts
Fiscal Year 2026
-
Strong growth is expected from the current portfolio and upcoming launches, with key data readouts in Alzheimer’s, atrial fibrillation, and pulmonary fibrosis anticipated by year-end. Strategic partnerships, disciplined spending, and a robust pipeline position the company for long-term, sustainable growth.
-
Strong financial discipline and portfolio growth underpin a robust pipeline, with six pivotal readouts expected in 2026 and over 10 new medicines targeted by 2030. Business development and R&D execution remain top priorities, with major opportunities in neuroscience, oncology, and hematology.
Fiscal Year 2025
-
Growth portfolio delivered double-digit revenue growth, offsetting legacy declines, with key products like Opdualag, Breyanzi, and Camzyos each surpassing $1B in annual sales. 2026 guidance projects $46B–$47.5B in revenue, strong Eliquis performance, and continued cost discipline.
-
A robust hematology pipeline is advancing with pivotal data expected for CELMoDs and CAR-T therapies, aiming to transform multiple myeloma and lymphoma care. Breyanzi leads the CD19 CAR-T market, and new assets are positioned for future growth and broader patient impact.
-
Key clinical programs are advancing, with Cobenfy and Camzyos showing strong commercial momentum and new indications in development. AI and efficiency initiatives are driving cost savings and accelerating R&D, while direct-to-patient strategies and robust business development support future growth.
-
Q3 2025 saw strong 17% growth in the portfolio, robust sales across key brands, and raised full-year revenue guidance. Strategic acquisitions and pipeline progress support long-term growth, while cost discipline and capital allocation remain priorities.
-
Cell therapy is at an inflection point, with innovation in CAR T platforms, expanded indications, and regulatory changes driving broader access. Manufacturing advances and outpatient delivery have fueled market leadership, while ongoing investments in off-the-shelf and in vivo approaches aim to unlock new opportunities in hematology and immunology.
-
Management highlighted strong Q2 growth, a robust late-stage pipeline, and disciplined financial strategy. Cobenfy's launch is progressing well, with broad access and high prescriber engagement. Key data readouts in oncology, neuroscience, and cardiovascular are expected over the next 12–18 months.
-
Q2 2025 delivered strong revenue and EPS growth, driven by robust demand across key brands and strategic partnerships. Guidance was raised for both revenue and EPS, with continued investment in pipeline and productivity initiatives.
-
Constructive policy engagement and a $40B US investment plan set the stage for growth. Major deals like the BioNTech partnership target leadership in oncology, while launches such as COBENFY and CAMZYOS outperform expectations. A robust pipeline aims for 10 new products and 30 indications by 2030.
-
Leadership is driving growth through portfolio expansion, cost discipline, and strategic M&A, while navigating regulatory and pricing pressures. Key pipeline assets and commercial launches are prioritized, with financial flexibility supporting innovation and resilience.
-
Shareholders heard updates on strong 2024 financials, pipeline progress, and strategic use of AI. All management proposals passed with high approval, while shareholder proposals on financial sustainability and DEI were overwhelmingly rejected. Dividend increases and leadership transitions were also highlighted.
-
Q1 saw robust double-digit growth in the core portfolio, with strong launches for COBENFY and OPDIVO QVANTIG, and multiple regulatory approvals. Full-year revenue and EPS guidance were raised, cost savings initiatives are on track, and the pipeline remains a key focus for long-term growth.
-
Key late-stage readouts are expected in immunology, cardiovascular, and neuroscience, including CAMZYOS, Milvexian, and Cobenfy. The development strategy emphasizes high unmet need, robust phase II data, and optimizing safety and efficacy, with several pivotal trials nearing completion.
-
Strong 2024 performance and a robust pipeline position the company for long-term growth, with major launches like Cobenfy and Camzyos, and significant data readouts expected in 2024. Market expansion, new indications, and next-generation therapies are key strategic focuses.
-
The company is executing a multi-year strategy to drive top-tier growth, focusing on a diversified portfolio, key product launches, and late-stage pipeline catalysts. Strong early results from new products and disciplined financial management support a positive long-term outlook.
Fiscal Year 2024
-
Delivered strong Q4 and full-year 2024 results, with double-digit growth in the key portfolio and robust launches for Cobenfy and Camzyos. 2025 guidance reflects generic headwinds in legacy products, offset by growth brands and a $2B cost savings initiative.
-
Management outlined a strategy focused on near-term execution and long-term growth, highlighting the COBENFY launch, robust pipeline updates, and continued business development. Financial discipline, portfolio efficiency, and resilience to policy changes underpin the outlook for 2025 and beyond.
-
Strong growth in the portfolio, major product launches, and robust clinical pipeline are driving transformation. Integration of recent acquisitions and a $1.5B savings initiative support long-term growth, while the company remains focused on execution and innovation.
-
The conference highlighted a broadened and prioritized pipeline, with major advances in oncology, neuropsychiatry, immunology, and cardiovascular disease. Key assets like Cobenfy and Milvexian are set for pivotal readouts, while cell therapy and radioligand programs drive future growth.
-
Growth portfolio revenues surged 20% year-over-year, now comprising half of total revenues, with strong contributions from new launches like Cobenfy and robust performance across oncology, cardiovascular, and hematology. Full-year revenue and EPS guidance were raised, reflecting solid execution, pipeline progress, and disciplined expense management.
-
The event highlighted robust progress in oncology, with new data supporting dual I-O regimens, expansion into novel modalities, and multiple registrational trials planned or underway. Key programs in lung, prostate, and breast cancer showed promising efficacy and safety, with a focus on overall survival as the primary endpoint.
-
Strong growth in key portfolio products is expected to continue, with major launches like KarXT and expanded access for Sotyktu and Breyanzi driving momentum. Regulatory and policy changes are seen as manageable, and a robust pipeline positions the company for long-term growth.
-
Strong Q2 growth and portfolio momentum are driving a strategic transformation focused on new launches, operational efficiency, and disciplined capital allocation. KarXT is set for a major 2025 launch, with robust pipeline progress in neuroscience and oncology, and confidence in managing IRA impacts.
-
Q2 saw strong growth in the portfolio, with revenues up 18% year-over-year and EPS at $2.07. Guidance for full-year revenue and EPS was raised, driven by robust performance in oncology, cardiovascular, and hematology, while immunology access improved.
-
The discussion highlighted a robust clinical pipeline in targeted protein degradation, with multiple CELMoDs and LDDs advancing in myeloma and lymphoma. Novel design strategies, translational insights, and collaborations drive differentiation, with key data expected in 2026.
-
Leadership is driving a focused transformation with resource reallocation, operational simplification, and disciplined capital allocation. Key product launches and pipeline catalysts are prioritized, with strong momentum in immunology, oncology, and cardiovascular. IRA and Part D changes are expected to be neutral overall, with growth clarity emerging over the next 18-24 months.